United Health Products Completes Multiple FDA Required Tests for HemoStyp®

HENDERSON, Nev., Dec. 18, 2017 -- United Health Products, Inc. (UHP) (OTC:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it has completed an array of tests required as a part of a FDA submission. The biocompatibility tests, which were conducted at independent laboratories Nelson Labs and EMSL Analytical, tested for irritability, sensitivity, cytoxcity, and absorption of the company’s HemoStyp product. Results from the tests exceeded the performance of any competitive products known to the company. The results will be published on the company’s website following presentation to the FDA and other international regulatory agencies in Australia and South Korea. 

Separately, UHP is pleased to announce that its South Korean distribution partner in South Korea has prepared a submission for HemoStyp with the South Korean Ministry of Food and Drug Safety (MFDS), to apply for a classification that would be analogous to the company’s Class III submissions with the USFDA and the Therapeutics Goods Administration in Australia. This submission is scheduled for early 2018.

About MFDS

The Ministry of Food and Drug Safety provides the vision of "Safe Food and Drug, Healthy People, Well-being Society", we are making extensive efforts to safeguard consumers and promote the public health by ensuring the safety of all foods, drugs, cosmetics, herbal medicines, and medical devices that we have in our daily lives. The importance of risk management for food and drug safety is ever growing and the scope of management is expanding. As more and more people are seeking to maintain a healthy lifestyle, it is crucial to ensure that the food and drugs they have are safe and effective. We, at the MFDS, are dedicated to advance our mission of protecting and promoting the health of the people in the same way we care for our own families, and help create a safer and healthier food and drug environment. http://www.mfds.go.kr/eng/index.do?nMenuCode=10

About United Health Products
United Health Products (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UHP is focused on identifying new markets and applications for its products, and expanding its current markets.

For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com 

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. 

Company Contact:    
United Health Products, Inc.    
877-358-3444 

IR Contact:  
PAN Consultants Ltd.
Philippe Niemetz
212 -344 - 6464